Fibroblast growth factor 23 in acute kidney injury

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 4, 2014, Pages 340-345

  Christov, Marta ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

FGF23; Mineral metabolism; Phosphate

Indexed keywords

CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D; FIBROBLAST GROWTH FACTOR;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; ARTIFICIAL VENTILATION; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HUMAN; IRON DEFICIENCY; MINERAL METABOLISM; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; VITAMIN METABOLISM; ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; METABOLISM; SIGNAL TRANSDUCTION;

ACUTE KIDNEY INJURY; ANIMALS; CALCITRIOL; FIBROBLAST GROWTH FACTORS; HUMANS; PARATHYROID HORMONE; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

EID: 84902251698     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000447021.51722.2f     Document Type: Review

References (42)

1. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26:345-348.
2. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98:6500-6505.
3. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113:561-568.
4. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64:2272-2279.
5. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16:2205-2215.
6. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584-592.
7. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305:2432-2439.
8. Christov M, Juppner H. Insights from genetic disorders of phosphate homeostasis. Semin Nephrol 2013; 33:143-157.
9. Zanchi C, Locatelli M, Benigni A, et al. Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ace inhibitor. PLoS One 2013; 8:e70775.
10. Spichtig D, Zhang H, Mohebbi N, et al. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int 2014; doi: 10.1038/ki.2013.526. [Epub ahead of print]
11. Pereira RC, Juppner H, Azucena-Serrano CE, et al. Patterns of FGF-23 DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009; 45:1161-1168.
12. Saji F, Shizaki K, Shimada S, et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol 2009; 111:59-66.
13. Lavi-Moshayoff V, Wasserman G, Meir T, et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299:F882-F889.
14. Burnett-Bowie SM, Henao MP, Dere ME, et al. Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res 2009; 24:1681-1685.
15. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79:1370-1378.
16. Bergwitz C, Banerjee S, Abu-Zahra H, et al. Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis. J Clin Endocrinol Metab 2009; 94:4267-4274.
17. Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 2011; 108:E1146-E1155.
18. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013; 28:1793-1803.
19. Shimada T, Urakawa I, Isakova T, et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010; 95:578-585.
20. Smith ER, Cai MM, McMohan LP, Holt SG. Biological variability of plasma intact and C-Terminal FGF23 measurements. J Clin Endocrinol Metab 2012; 97:3357-3365.
21. Yuan B, Feng JQ, Bowman S, et al. Hexa-D-Arginine treatment increases 7B2*PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype. J Bone Miner Res 2013; 28:56-72.
22. Faul C, Amaral MP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393-4408.
23. Touchberry CD, Green TM, Tchikrizov V, et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab 2013; 304:E863-E873.
24. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119:2545-2552.
25. Bacchetta J, Sea JL, Chun RF, et al. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res 2013; 28:46-55.
26. Druml W, Schwarzenhofer M, Apsner R, Horl WH. Fat-soluble vitamins in patients with acute renal failure. Miner Electrolyte Metab 1998; 24:220-226.
27. Llach F, Felsenfeld AJ, Haussler MR. The pathophysiology of altered calcium metabolism in rhabdomyolysis-induced acute renal failure. Interactions of parathyroid hormone, 25-hydroxycholecalciferol, and 1,25- dihydroxycholecalciferol. N Engl J Med 1981; 305:117-123.
28. Saha H, Mustonen J, Pietilla K, Pasternack A. Metabolism of calcium and vitamin D3 in patients with acute tubulointerstitial nephritis: a study of 41 patients with nephropathia epidemica. Nephron 1993; 63:159-163.
29. Leaf DE, Waiker SS, Wolf M, et al. Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. Clin Endocrinol (Oxf) 2013; 79:491-498.
30. Demirjian S, Teo BW, Guzman JA, et al. Hypophosphatemia during continuous hemodialysis is associated with prolonged respiratory failure in patients with acute kidney injury. Nephrol Dial Transplant 2011; 26:3508-3514.
31. Schiffl H, Lang SM. Severe acute hypophosphatemia during renal replacement therapy adversely affects outcome of critically ill patients with acute kidney injury. Int Urol Nephrol 2013; 45:191-197.
32. Leaf DE, Wolf ML, Stern L. Elevated FGF-23 in a patient with rhabdomyolysisinduced acute kidney injury. Nephrol Dial Transplant 2010; 25:1335-1337.
33. Zhang M, Hsu R, Hsu CY, et al. FGF-23 and PTH levels in patients with acute kidney injury: a cross-sectional case series study. Ann Intensive Care 2011; 1:21.
34. Leaf DE, Wolf M, Waikar SS, et al. FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol 2012; 7:1217-1223.
35. Ali FN, Hassinger A, Price H, Langman CB, et al. Preoperative plasma FGF23 levels predict acute kidney injury in children: results of a pilot study. Pediatr Nephrol 2013; 28:959-962.
36. Isakova T, Houston J, Santacruz L, et al. Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure. Pediatr Nephrol 2013; 28:2035-2042.
37. Christov M, Waikar SS, Pereira RC, et al. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int 2013; 84:776-785.
38. Rodriguez-Ortiz ME, Lopez I, Munozcastaneda JR, et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 2012; 23:1190-1197.
39. David V, Dai B, Martin A, et al. Calcium regulates FGF-23 expression in bone. Endocrinology 2013; 154:4469-4482.
40. Goebel S, Lienau J, Rammoser U, et al. FGF23 is a putative marker for bone healing and regeneration. J Orthop Res 2009; 27:1141-1146.
41. Wang WJ, Chao CT, Huang YC, et al. The impact of acute kidney injury with temporary dialysis on the risk of fracture. J Bone Miner Res 2014; 29:676-684.
42. Basu RK, Wheeler DS. Kidney-lung cross-Talk and acute kidney injury. Pediatr Nephrol 2013; 28:2239-2248.